Efficacy of antibody drug conjugate (ADC) by mRNA expression of targeted genes in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2

被引：0

作者：

Fujisawa, T. ^{[1
]}

Nakamura, Y. ^{[1
]}

Sakamoto, N. ^{[2
]}

Hashimoto, T. ^{[1
]}

Nagamine, M. ^{[3
]}

Kuwata, T. ^{[4
]}

Ishii, G. ^{[3
]}

Yamashita, R. ^{[5
]}

Morizane, C. ^{[6
]}

Nonomura, N. ^{[7
]}

Iwata, H. ^{[8
]}

Okano, S. ^{[9
]}

Watari, H. ^{[10
]}

Namikawa, K. ^{[11
]}

Shibuki, T. ^{[1
]}

Imai-Sumida, M. ^{[1
]}

Bando, H. ^{[1
]}

Radovich, M. ^{[12
]}

Sledge, G. ^{[13
]}

Yoshino, T. ^{[1
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Promot Drug & Diagnost Dev, Kashiwa, Chiba, Japan

[2] Natl Canc Ctr Exploratory Oncol Res & Clin Trial, Div Pathol, Kashiwa, Chiba, Japan

[3] Natl Canc Ctr Hosp East, Dept Pathol & Clin Labs, Kashiwa, Chiba, Japan

[4] Natl Canc Ctr Hosp East, Dept Genet Med & Serv, Kashiwa, Chiba, Japan

[5] Natl Canc Ctr Hosp East, Div Translat Informat, Kashiwa, Chiba, Japan

[6] NCCH Natl Canc Ctr Hosp, Dept Hepatobiliary & Pancreat Oncol, Tsukiji Campus,Chuo Ku, Tokyo, Japan

[7] Osaka Univ, Fac Med, Grad Sch Med, Urol Dept, Suita, Osaka, Japan

[8] Aichi Canc Ctr Hosp, Breast Oncol Dept, Nagoya, Aichi, Japan

[9] Natl Canc Ctr Hosp East, Head & Neck Med Oncol Dept, Kashiwa, Chiba, Japan

[10] Hokkaido Univ Hosp, Hematol Oncol, Sapporo, Hokkaido, Japan

[11] NCCH Natl Canc Ctr Hosp, Dermatol Oncol Dept, Chuo Ku, Tokyo, Japan

[12] Caris Life Sci, Precis Med, Phoenix, AZ USA

[13] Caris Life Sci, Lab & Specimen Receiving, Phoenix, AZ USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2206

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

201P

引用

页码：S297 / S298

页数：2

共 50 条

[41] Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors
Zammarchi, Francesca
Reinert, Halla W.
Janghra, Narinder
Corbett, Simon
Mellinas-Gomez, Maria
Chowdhury, Sajidah
Arora, Neha
Tyrer, Peter
Bertelli, Francois
Williams, David G.
Howard, Philip W.
Hartley, John A.
van Berkel, Patrick H.
CANCER RESEARCH, 2017, 77
[42] Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
Yingying Xu
Yakun Wang
Jifang Gong
Xiaotian Zhang
Zhi Peng
Xinan Sheng
Chenyu Mao
Qingxia Fan
Yuxian Bai
Yi Ba
Da Jiang
Fen Yang
Changsong Qi
Jian Li
Xicheng Wang
Jun Zhou
Ming Lu
Yanshuo Cao
Jiajia Yuan
Dan Liu
Zhenghang Wang
Jianmin Fang
Lin Shen
Gastric Cancer, 2021, 24 : 913 - 925
[43] First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors
Zhang, Jian
Du, Yiqun
Meng, Yanchun
Liu, Xiaojun
Mu, Yuxin
Liu, Yunpeng
Shi, Yehui
Wang, Jufeng
Zang, Aimin
Gu, Shanzhi
Liu, Tianshu
Zhou, Huan
Guo, Hongqian
Xiang, Silong
Zhang, Xialu
Wu, Suqiong
Qi, Huanhuan
Li, Mengke
Hu, Xichun
NPJ PRECISION ONCOLOGY, 2024, 8 (01)
[44] Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies
Jonasch, Eric
Call, Justin
Kambhampati, Swetha
Caimi, Paolo
Curti, Brendan
Diefenbach, Catherine
Heath, Elisabeth
Park, Steven
Kornblum, Noah
Li, Weidong
Reimers, Melissa
Spurgeon, Stephen
Vaishampayan, Ulka
Ye, Dingwei
Zhang, Li
Zhao, Weili
Chen, Zhu
Hunder, Naomi
Ma, Sharon
Song, Eric
Garmezy, Benjamin
ONCOLOGIST, 2023, 28
[45] Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study
Zhou, Yi-Xin
Wang, Jia-Ling
Mu, Xiao-Li
Zhu, Ya-Juan
Chen, Ye
Liu, Ji-Yan
AGING-US, 2023, 15 (24): : 15473 - 15488
[46] Dose escalation and expansion results from the phase I study of F0024, a trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Du, Yiqun
Meng, Yanchun
Wang, Jingfen
Wang, Ying
Wu, Fan
Chen, Yu
Chen, Lilin
Qing, Lihua
Qiao, Yaya
Liu, Kezhen
Sun, Wenyi
Li, Xiaowen
Zhang, Jian
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
Xu, Yingying
Wang, Yakun
Gong, Jifang
Zhang, Xiaotian
Peng, Zhi
Sheng, Xinan
Mao, Chenyu
Fan, Qingxia
Bai, Yuxian
Ba, Yi
Jiang, Da
Yang, Fen
Qi, Changsong
Li, Jian
Wang, Xicheng
Zhou, Jun
Lu, Ming
Cao, Yanshuo
Yuan, Jiajia
Liu, Dan
Wang, Zhenghang
Fang, Jianmin
Shen, Lin
GASTRIC CANCER, 2021, 24 (04) : 913 - 925
[48] 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.
Zhang, Jian
Liu, Rujiao
Gao, Shuiping
Yang, Huijuan
Chen, Jian
Yuan, Fang
Liu, Jiyan
Guo, Hongqian
Zhang, Shun
Li, XingYa
Yao, Xin
Bai, Ming
Bu, Hualei
Li, Yinyin
Hu, Changlu
Li, Xiumin
Wang, Zhen
Wang, ShanBing
Lou, Hanmei
Feng, Zhe
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[49] Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.
Strickler, John H.
Nemunaitis, John J.
Weekes, Colin D.
Ramanathan, Ramesh K.
Angevin, Eric
Morgensztern, Daniel
Heist, Rebecca Suk
Bauer, Todd Michael
Kaminker, Patrick
Fan, Xiaolin
Siggelkow, Sara
Wong, Shekman
Reilly, Edward B.
Afar, Daniel E.
Naumovski, Louie
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[50] A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).
Gomez-Roca, Carlos Alberto
Boni, Valentina
Moreno, Victor
Morris, John Charles
Delord, Jean-Pierre
Calvo, Emiliano
Papadopoulos, Kyriakos P.
Rixe, Olivier
Cohen, Patrick
Tellier, Alexia
Ziti-Ljajic, Samira
Tolcher, Anthony W.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →